High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia

Am J Hematol. 2012 Dec;87(12):E133. doi: 10.1002/ajh.23349. Epub 2012 Oct 31.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Alemtuzumab
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm
  • Female
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / adverse effects
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Male
  • Middle Aged
  • Salvage Therapy
  • Vidarabine / analogs & derivatives
  • Vidarabine / pharmacology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Glucocorticoids
  • Alemtuzumab
  • Vidarabine
  • ofatumumab
  • fludarabine